Objective To measure the costs and estimate the cost-effectiveness of the ProTEST package of tuberculosis/human immunodeficiency virus (TB/HIV) interventions in primary health care facilities in Cape Town, South Africa. Methods We collected annual cost data retrospectively using ingredients-based costing in three primary care facilities and estimated the cost per HIV infection averted and the cost per TB case prevented. Findings The range of costs per person for the ProTEST interventions in the three facilities were: US$ 7-11 for voluntary counselling and testing (VCT), US$ 81-166 for detecting a TB case, US$ 92-183 for completing isoniazid preventive therapy (IPT) and US$ 20-44 for completing six months of cotrimoxazole preventive therapy. The estimated cost per HIV infection averted by VCT was US$ 67-112. The cost per TB case prevented by VCT (through preventing HIV) was US$ 129-215, by intensified case finding was US$ 323-664 and by IPT was US$ 486-962. Sensitivity analysis showed that the use of chest X-rays for IPT screening decreases the cost-effectiveness of IPT in preventing TB cases by 36%. IPT screening with or without tuberculin purified protein derivative screening was almost equally cost-effective. Conclusion We conclude that the ProTEST package is cost saving. Despite moderate adherence, linking prevention and care interventions for TB and HIV resulted in the estimated costs of preventing TB being less than previous estimates of costs of treating it. VCT was less expensive than previously reported in Africa.
Introduction
With an antenatal human immunodeficiency virus (HIV) prevalence of 29.5% and an estimated 6.29 million people infected, 1 South Africa has the largest number of people living with HIV/ acquired immunodeficiency syndrome (AIDS) in the world. 2 HIV increases tuberculosis (TB) incidence by reactivation of latent infection 3 and rapid progression of recent infection. 4 With increasing HIV prevalence, TB incidence has risen throughout sub-Saharan Africa. 5, 6 In South Africa, the incidence of TB increased from 187/100 000 in 1989 7 to 599/100 000 in 2004. 8 Following the recommendations by national reviews for improved collabo--ration between the TB and HIV/AIDS programmes in South Africa, 9, 10 four TB/HIV Pilot Districts were initiated in 1999. These districts participated in ProTEST, 11 a WHO supported package of TB/HIV interventions by providing voluntary counselling and testing (VCT) with rapid HIV testing, screening for TB through intensified case-finding (ICF), isoniazid preventive therapy (IPT), cotri--moxazole preventive therapy (CPT), and improved management of opportunistic infections. ProTEST aimed to decrease the transmission of HIV through VCT, decrease the transmission of TB through ICF and prevent the reactivation of TB through IPT. 12 Cost and cost-effectiveness data for ProTEST interventions are important for programme managers to decide what is affordable for expanded implementa--tion. The data are relevant in the era of antiretroviral treatment (ART) pro--grammes because VCT is necessary to identify HIV-infected persons and ICF, IPT and CPT remain part of the com--prehensive package of HIV care. There are few studies in developing countries on the cost-effectiveness of VCT, 13 rapid HIV testing, 14 IPT [15] [16] [17] [18] [19] and CPT. 20 We measured the costs and estimated the cost-effectiveness of the ProTEST package of TB/HIV interventions in Cape Town, South Africa.
Methods

Setting
The Central District of Cape Town, with a population of 296 000, consists of urban/peri-urban areas with vast socio--economic disparities. The antenatal HIV prevalence was 17% in 2001 and the TB incidence was 488/100 000 in 2002. 21 Using purposive sampling, we chose three public primary health care facilities -a community health centre (CHC), a primary health care (PHC) clinic and a sexually transmitted infections (STI) clinic -from the 12 facilities that par--ticipated in ProTEST (Table 1 , web ver--sion only, available from: http://www. who.int/bulletin). All facilities promoted VCT to self-presenting and antenatal clients as well as TB and STI patients, and provided improved management of HIV-related infections. The CHC and PHC clinic also offered ICF (TB symp--tom screening for HIV-positive patients, and sputum smear investigations as well as chest X-ray for TB symptomatics), IPT (isoniazid 300 mg daily for six months for HIV-positive patients with no TB symptoms, a normal chest X-ray, and a positive tuberculin skin test) and CPT (life-long cotrimoxazole 480 mg daily for patients with HIV/AIDS, WHO clinical stage III or IV) (Fig. 1) . We evaluated only VCT in the STI clinic and the complete ProTEST package in the CHC and PHC clinics.
Cost analysis
Following the Costing guidelines for HIV/ AIDS prevention strategies developed by UNAIDS, 22 we collected the costs incurred by public and nongovernmen--tal organization (NGO) health-care providers retrospectively, using ingredi--ents-based costing, i.e. costing each com--ponent of an activity, including capital and recurrent costs for one financial year. Financial costs represented actual expenditure, while economic costs were financial costs plus the estimated value of goods or services with no financial transactions and some adjusted financial costs when the price paid did not reflect the cost of using it elsewhere.
We did not include the costs of research. We could not measure the costs of drugs used in the treatment of opportunistic infections because they could not be separated from drugs that were dispensed for other infections. The costs of diagnostic tests for HIV and TB and the costs of prophylactic drugs were included. Start-up costs, including initial training costs, were regarded as capital costs because the effect of the activities lasted for more than a year. We annuatized the capital costs using a discount rate of 8% (the discount rate most widely used in South Africa for that time), 23 assuming that the life-span of buildings is 30 years, furniture 10 years, equipment and vehicles five years and initial training five years. Life-spans were estimated based on consultations with district health officials.
Sources of recurrent cost data in--cluded financial records and interviews with project staff. Costs are presented in US$ (US$ 1 = R 9.28, exchange rate for South African rand for the period April 2001 to March 2002). 24 Total costs were apportioned to the following project activities: health education, pre-test counselling, HIV testing, post-test counselling, screening for IPT/CPT, follow-up for IPT/CPT, management of opportunistic infections (OIs) and supervision/training/mentor--ship. All counsellor salary costs were allocated to VCT. We calculated the weighted average personnel cost per minute from estimates made by clinical staff of the proportion of time that they spent on ProTEST. We also interviewed clinical staff to estimate the average amount of time they spent on screening and follow-up of a client for prophylaxis. This time multiplied by the cost per minute multiplied by the number of clients gave the costs for screening and follow-up. Other costs (such as build--ings, furniture, equipment, vehicles and maintenance) of the health services were multiplied by the proportion of all clinic visits that were for ProTEST to determine the amount that should be allocated to ProTEST. We divided these costs equally between project activities.
Estimating impact
Since we could not measure the efficacy of ProTEST interventions directly, re--sults from recently published efficacy studies were used to estimate the impact of interventions, with special attention to studies done in African countries with a high burden of TB and HIV.
To estimate the cost per HIV infec--tion averted, we used the results of a re--cent multicentre randomized controlled trial of VCT, which found that VCT decreased risk behaviours and estimated that for every 100 people accessing VCT, 10 HIV infections are averted (in sensi--tivity analyses, this ranged from 1 to 24 HIV infections averted). 13 We developed a model that used the risk of primary TB disease after infec--tion and risk of reactivation of latent TB infection in HIV-positive and HIVnegative adults, [25] [26] [27] [28] [29] [30] [31] for estimating the number of TB cases averted each year (over a period of 10 years), by prevent--ing HIV infection. We estimated that for every 100 people accessing VCT, 10 HIV cases and 5.2 TB cases would be prevented over 10 years.
For estimating the cost per TB case prevented through ICF it was assumed that every TB case infects 10-14 people per year and results in one more TB case, 32 that ICF might decrease the infectious period from 9.6 months in HIV-infected people 33 by 30%, and that 85% of detected cases will remain noninfectious (successfully treated or died). 34 For every 100 TB cases detected by ICF, 25 TB cases would be prevented.
For IPT using tuberculin purified protein derivative (PPD) tests for screen--ing, the estimated cost per TB case averted was based on the following con--servative assumptions: IPT decreases TB incidence by 60% (95% confidence interval (CI): 35-76%) for two years in PPD-positives (results from a metaanalysis of intention to treat clinical trials with 60-80% adherence), 35 annual inci--dence of TB in PPD-positive HIV-posi--tive people is 8%; and each HIV-positive TB case causes one other case. Assuming similar efficacy to clinical trials, for every 100 people completing IPT using PPD screening, 19 (95% CI: 11-24) TB cases are averted.
Sensitivity analysis
We considered the cost-effectiveness of different screening protocols (including the WHO recommended protocol 36 ) in the sensitivity analysis and included dis--counting the cases of TB prevented in the future by VCT in the sensitivity analysis at a discount rate of 5% cumulatively over 1 to 10 years. 37, 38 We also conducted univariate sensitivity analyses with several variables for the PHC clinic.
Findings Cost analysis
All costs are given in US dollars (US$). The unit costs were US$ 1.07 for an HIV screening test, US$ 2.01 for an HIV confirmatory test, US$ 3.29 for an HIV enzyme-linked immunosorbent assay (ELISA), US$ 2.20 for a sputum smear examination for TB, US$ 5.12 for a sputum TB culture, US$ 14.43 for a chest X-ray, US$ 0.73 for a PPD test; US$ 0.27/month for isoniazid; and US$ 0.40/month for cotrimoxazole.
The summary of total costs is given in Table 2 (web version only, available from: http://www.who.int/bulletin). We found that the total economic cost for one year of ProTEST activities was US$ 21 623 in the CHC, US$ 47 280 in the PHC clinic and US$ 36 575 in the STI clinic. The highest costs were associated with the management of OIs in facilities offering comprehensive clinical services followed by VCT services (the sum of pre-and post-test counselling and test--ing). The combined cost of screening and follow-up for IPT and CPT was similar to the cost of TB/HIV/STI education. Start-up and coordination costs were low. Financial costs were slightly higher than economic costs in the PHC clinic and STI clinic because NGO counsellor sala--ries (actual costs, considered "financial") were higher than the government coun--sellor salaries (costs required for scaling up, considered "economic").
Personnel costs accounted for a much higher proportion of the total costs than the cost of supplies: 82% versus 12% in the CHC, 85% versus 11% in the PHC clinic and 78% versus 17% in the STI clinic. Other capital costs (1% in all), and recurrent vehicle and building costs (1% in the CHC and PHC clinic and 2% in the STI clinic) were small.
The STI clinic had the largest num--ber of VCT clients (Table 3 , web version only, available from: http://www.who. int/bulletin). At all sites, most people who received pre-test counselling were tested for HIV (97-99%). HIV preva--lence was lower in the CHC (20%) and STI clinic (21%) than in the PHC clinic
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(27%). The 34 TB cases identified by ICF represented 4% of the 781 cases registered at the PHC clinic over the same period. All TB cases diagnosed at the CHC were referred to a TB clinic; the numbers referred were not recorded. The PHC clinic screened the highest numbers for prophylaxis and achieved better adherence rates than the CHC. The proportion of screened HIV-positive clients who started IPT was 15-16% and those who started CPT was 38-57%. Our results showed that the unit costs were similar for VCT but lower for ICF, IPT and CPT in the PHC clinic compared to the CHC (Table 4 ). The cost per six person-months of providing prophylaxis after screening was US$ 6-9 for IPT and US$ 6-8 for CPT.
The cost per person completing VCT ranged from US$ 7 to US$ 11 ( Table 5 ). The cost per TB case detected and cost per person completing six months of prophylaxis were about half as expensive at the PHC clinic than at the CHC. 
Estimating impact
We found that the estimated cost per HIV infection averted through VCT ranged from US$ 67 in the STI clinic to US$ 112 in the CHC. The estimated cost per TB case prevented was US$ 129-215 by VCT, US$ 323-664 by ICF and US$ 486-962 by IPT (Table 5 ).
Sensitivity analysis
The discounted health effect of VCT was 3.7 TB cases prevented for every 100 people completing VCT compared to 5.2 TB cases prevented with no discount--ing. This increased the cost per TB case prevented by VCT to US$ 181-302.
Follow-up interviews with managers and staff showed that staff overestimated the time spent for each intervention when they used time sheets. The sensi--tivity analysis showed higher costs for all interventions when using time sheets (Table 6 , web version only, available from: http://www.who.int/bulletin).
Lay counsellors and rapid HIV test--ing were more cost-effective as our results showed that using nurse counsellors increased the cost per person post-test counselled by 182% and using ELISA increased the cost by 23%.
The cost per person completing IPT and the cost per TB case prevented were affected by changes in the screening protocol. Removing chest X-ray from the IPT screening protocol decreased the cost per TB case detected by 40% and decreased the cost per person completing IPT by 36% (Table 6 ).
Discussion
Cost analysis
Our findings show that total costs varied widely among the facilities and reflected the number and category of staff involved, the services offered, HIV prevalence and the number of clients. Personnel accounted for the highest pro--portion (78-85%) of total costs due to the labour-intensive nature of VCT and HIV clinical care. Cost of supplies was a much lower proportion of total costs (11-17%) reflecting the low cost of rapid
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Harry Peter Hausler et al. HIV tests, isoniazid and cotrimoxazole. The high proportion of total costs at--tributable to personnel and the fact that salary costs are lower in many other African countries should be considered when assessing the affordability of these interventions in other settings. The cost per person post-test coun--selled was lower in the STI clinic than in the other facilities because of the higher number of persons coming for testing and the exclusive use of lay counsellors. The cost per person post-test counselled in our study (US$ 7-11) across all three sites was lower than that reported from Kenya (US$ 30) and the United Repub--lic of Tanzania (US$ 32). 13 This may be due to the use of lay counsellors instead of professional counsellors and rapid HIV tests instead of laboratory-based ELISAs. A study from South Africa showed that the cost per person post-test counselled almost halved from US$ 20.95 to US$ 11.30 by using rapid tests compared to ELISA.
14 In our study using rapid HIV tests, almost every person tested received their HIV test results (99-100%) where--as with the use of ELISAs in the study in Kenya and the United Republic of Tanzania a smaller proportion of people (70-95%) received their results. 39 The cost per clinical intervention (ICF, IPT, CPT) was lower at the PHC clinic than at the CHC. This was mostly due to the larger proportion of HIVpositive clients starting and completing prophylaxis as the weighted average personnel cost per minute was found to be similar for both facilities.
The cost per TB case detected at the PHC clinic was half that at the CHC (US$ 81 versus US$ 166). This is partial--ly due to the higher TB incidence at the PHC clinic (1353/100 000) than in the whole population of the Central District (488/100 000) resulting in more cases being diagnosed (42% versus 24% of symptomatics diagnosed with TB). TB cases detected by ICF represented 4% of the PHC clinic's total TB case-load.
The cost per person completing six months of IPT incremental to ICF (US$ 51-110) was considerably lower than the cost per person completing IPT including ICF (US$ 92-183). Thus, once a programme decides to do ICF, the additional cost of providing IPT would be relatively small.
The cost per person completing six months of IPT (US$ 92) with 57% adherence was higher than the cost re--ported in Uganda with 62% adherence (US$ 24) 19 and from a modelling study in Zambia with an assumed 63% adher--ence (US$ 42), 18 due to the higher cost of personnel and lower adherence to IPT in South Africa.
Estimating impact
Our estimates of cost per HIV infection averted by VCT (US$ 67-112) com--pares favourably to the cost per HIV infection averted by other HIV preven--tion interventions, such as improved management of STIs (US$ 280) 40 and nevirapine to prevent mother-to-child transmission of HIV (US$ 318). 41 Our results on cost per TB case pre--vented through VCT (US$ 129-215), ICF (US$ 323-664) and IPT (US$ 486-962) were less than the cost of treat--ing a new case of TB (US$ 823-1362) reported in a previous study from Cape Town. 42 The cost of providing IPT is also likely to be less than the cost of treat--ing a TB case in other African countries where a smaller proportion of IPT costs would be for personnel and a higher 43 and hospitalizations in symptomatic HIV-positive people by 43% (95% CI: 25-57%). 44 An observational cohort in Cape Town showed similar results with CPT decreasing mortality by 44% (95% CI: 15-67%) and the incidence of severe HIV-related illnesses by 48% (95% CI: 32-62%). 45 Another study from Cape Town has reported the number of hos--pitalization days for people not on ART as 1.84 per year at a cost of US$ 206. 46 Therefore, if CPT decreased the cost of hospitalization by even 25% it would be cost-saving in this setting.
Sensitivity analysis
The sensitivity analysis showed higher costs for all interventions when using time sheets, highlighting the impor--tance of methodologies for measuring personnel time and costs. Lower salaries for lay counsellors make their involve--ment more cost-effective than nurse counsellors. We assumed that the quality and effectiveness of their counselling is similar to nurse counsellors as has been found previously in South Africa. 47 Discounting TB cases prevented in the future by VCT increased the cost per TB case prevented by 140% from US$ 129-215 to US$ 181-302, which remained less than the cost of treating a TB case.
The adherence to IPT at the PHC clinic was 57%. Setting adherence at 62%, as for other studies, the cost per person completing IPT remained higher (US$ 85) than in Uganda (US$ 24) 19 and Zambia (US$ 42). 18 High adher--ence levels (>95%) have been obtained with antiretroviral programmes in South Africa through adherence counselling, support groups, pill boxes, drug iden--tification charts, daily schedules, diaries and treatment literacy educational mate--rials. 48 We suggest that the cost-effective--ness of similar interventions to improve adherence to IPT be evaluated.
Limitations
One limitation of this study was that the three facilities were purposively sampled rather than randomly selected. While assessing the generalizability of the results, the following factors should be considered: urban/periurban/rural setting, HIV prevalence, TB incidence, number of staff and salary levels. The following factors would decrease costeffectiveness: settings with fewer patients per staff member, lower HIV prevalence, lower TB incidence and higher salaries.
Our estimates of the impact of VCT on HIV prevention were based on a study 39 that measured changes in risk be--haviours and estimated changes in HIV incidence in Kenya, United Republic of Tanzania, and Trinidad and Tobago. We do not know if VCT in Cape Town was as effective as in that study, but a similar model of risk-reduction counselling was used and the communities had a similar HIV prevalence.
Another limitation of our study was that confidence intervals were not calcu--lated for ascertaining the degree of cer--tainty of cost-effectiveness estimates.
Policy implications
A study from Botswana showed that of the 560 clients screened only one case of TB was detected by chest X-ray and a large proportion of clients (18%) were lost to follow-up. 49 Our sensitiv--ity analysis found that not using chest X-rays (with or without PPD) was the most cost-effective IPT screening pro--tocol. It decreased the cost per TB case prevented by 36%. We recommend that the requirement for chest X-rays as part of the screening process for IPT in the WHO guidelines be removed.
Although excluding PPD decreases the cost per person completing IPT by 60%, the cost per TB case prevented de--creases only by 4% because the efficacy of IPT is lower. PPD increases costs for screening (tuberculin, syringes, needles, personnel time) and for patients (time and transport to return for skin reactions to be read). There are also technical prob--lems in administering and reading the test correctly. However, not doing PPD exposes many people to isoniazid (with its potential side effects) who might not benefit from it and increases the burden on health services (more people starting isoniazid and being followed up). Given that the cost-effectiveness of both approaches is similar, WHO's recommendations remain appropriate: PPD testing should be done, and where it is not feasible, it can be omitted when the prevalence of TB infection is greater than 30% or in high-risk groups.
To assess the affordability of inter--ventions, we suggest that average cost data be combined with the number of people eligible for each intervention and compared with the available resources. Interventions are likely to become more cost-effective as the number of people accessing services increases.
Assuming that 20% of adults test HIV positive and, among HIV-infected clients, 15% are eligible for IPT, 40% are eligible for CPT and 95% complete prophylaxis, the total package includ--ing VCT would cost US$ 19 366 000-30 545 000. This includes testing 2 million people (about 10% of the adult population of South Africa at a cost of US$ 14-22 million), screening for ICF/IPT (US$ 2.8-4.8 million), screen--ing for CPT (US$ 400 000-800 000), providing IPT for six months (US$ 342 000-513 000) and providing CPT for one year (US$ 1 824 000-2 432 000). South Africa has allocated US$ 400 mil--lion for a comprehensive plan to provide HIV care in 2005-06, with US$ 120 million for antiretroviral drugs. 50 In this context, the ProTEST package is afford--able in South Africa.
Conclusions
We conclude that VCT using lay coun--sellors and rapid HIV testing is a costeffective intervention to prevent HIV and TB in South Africa. VCT services should be expanded for prevention and to link HIV-positive clients to care and support. Cost-saving interventions such as, ICF, IPT and CPT should be offered at all primary health care facilities in South Africa for HIV-positive clients. The use of chest X-rays for IPT screen--ing decreases the cost-effectiveness of IPT. PPD screening does not influence the cost-effectiveness of IPT to prevent TB.
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Resumen
Costo de las medidas de control de la tuberculosis/VIH en centros de atención primaria de Ciudad del Cabo, Sudáfrica
Objetivo Medir los costos y estimar la costoeficacia del paquete ProTEST de intervenciones contra la tuberculosis/virus de la inmunodeficiencia humana (tuberculosis/VIH) en establecimientos de atención primaria de Ciudad del Cabo, Sudáfrica. Métodos Reunimos retrospectivamente datos anuales sobre costos utilizando sistemas de determinación de los costos basados en componentes en tres establecimientos de atención primaria, para poder así estimar el costo asociado a cada infección por VIH evitada y el costo por caso de tuberculosis prevenido. Resultados Los intervalos de los costos por persona para las intervenciones de ProTEST en los tres centros fueron los siguientes: US$ 7 -11 para el asesoramiento y pruebas voluntarias (APV), US$ 81 -166 para la detección de un caso de tuberculosis, US$ 92 -183 para el régimen completo de terapia preventiva con isoniazida (TPI) y US$ 20 -44 para el tratamiento preventivo con cotrimoxazol durante seis meses. El costo estimado por infección por VIH evitada mediante APV fue de US$ 67 -112. El costo por caso de tuberculosis prevenido mediante APV (gracias a la prevención de la infección por VIH) fue de US$ 129 -215, mediante la búsqueda intensificada de casos, de US$ 323 -664, y mediante TPI, de US$ 486 -962. El análisis de sensibilidad demostró que el uso de radiografías torácicas en el cribado para TPI reduce en un 36% la costoeficacia de ésta como medio de prevención de los casos de tuberculosis. El cribado para TPI tuvo casi la misma costoeficacia con o sin cribado mediante derivados proteínicos purificados de la tuberculina. Conclusión Llegamos a la conclusión de que el paquete ProTEST permite ahorrar costos. Pese a la moderada observancia de los tratamientos, vinculando las intervenciones de prevención y atención para la tuberculosis y el VIH, los costos estimados para la prevención de la tuberculosis fueron inferiores a las estimaciones anteriores de los costos asociados al tratamiento de la misma. Las medidas de APV fueron menos costosas de lo que hasta ahora se había señalado en África. 
‫ملخص‬ ‫أفريقيا‬ ‫جنوب‬ ‫تاون،‬ ‫كيب‬ ‫يف‬ ‫األولية‬ ‫الصحية‬ ‫الرعاية‬ ‫افق‬ ‫مر‬ ‫يف‬ ‫باإليدز‬ ‫افق‬ ‫املرت‬ ‫السل‬ ‫مكافحة‬ ‫اءات‬ ‫إجر‬ ‫تكاليف‬
